Brittany Cote

Articles

Shah Highlights Novel Agents in Gastrointestinal Cancers

June 8th 2020

Manish A. Shah, MD, discusses the emerging agent zolbetuximab and the antibody-drug conjugate trastuzumab deruxtecan as treatment options for patients with gastric and GEJ cancers.

Ensituximab Shows Modest Single-Agent Activity in CRC, Combinations to Be Explored

June 8th 2020

The novel chimeric monoclonal antibody ensituximab demonstrated modest clinical activity and was found to be well tolerated in patients with heavily pretreated, refractory colorectal cancer.

Research Efforts Abound in Rapidly Evolving BRAF-Mutant Melanoma Paradigm

June 8th 2020

Charles L. Sawyers, MD, provides additional insight into the IMspire150 and SWOG S1320 trials presented at the 2020 AACR Annual Virtual Meeting I and underscored the need for additional research in this space.

Shah Highlights Novel Agents in Gastric Cancer

June 8th 2020

Manish A. Shah, MD, discusses the emerging agent zolbetuximab and the antibody-drug conjugate trastuzumab deruxtecan as treatment options for patients with gastric and GEJ cancers.

Drakaki Describes Efforts to Leverage Immunotherapy in Urothelial Carcinoma

June 4th 2020

Alexandra Drakaki, MD, discusses the ongoing research efforts being made in urothelial cancer, unmet needs and challenges faced in the space, and work that is generating further interest in the field.

Lopes Describes Approach for Discontinuing Immunotherapy in Metastatic Lung Cancer

May 27th 2020

Gilberto de Lima Lopes, MD, discusses the appropriate duration of immunotherapy in lung cancer, treatment-related adverse events, and remaining challenges faced in the space.

Expert Explains Effect of Age and Gender on Outcomes in RCC

May 21st 2020

Rana R. McKay, MD, sheds light on the impact of age and gender on the outcomes of patients with RCC, the implications of clinical determinants on toxicity, and where future research efforts will focus.

Expert Explains Effect of Age and Gender on Outcomes in RCC

May 21st 2020

Rana R. McKay, MD, sheds light on the impact of age and gender on the outcomes of patients with RCC, the implications of clinical determinants on toxicity, and where future research efforts will focus.

Chaft Crafts Considerations for Restarting Immunotherapy in Lung Cancer

May 19th 2020

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

Chaft Crafts Considerations for Restarting Immunotherapy in Lung Cancer

May 19th 2020

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

SNDX-5613 Shows Early Promise in Acute Leukemias

May 14th 2020

Michael J. Thirman, MD, further discusses the novel compound, SNDX-5613, and sheds light on the next steps for this research.

PET Scans and Novel Therapies Propel Progress in Hodgkin Lymphoma

May 13th 2020

Tatyana Feldman, MD, discusses the significance of PET-adapted strategies in Hodgkin lymphoma, novel therapies that have emerged in the pipeline, and where future research is headed.

PET Scans and Novel Therapies Propel Progress in Hodgkin Lymphoma

May 12th 2020

Tatyana Feldman, MD, discusses the significance of PET-adapted strategies in Hodgkin lymphoma, novel therapies that have emerged in the pipeline, and where future research is headed.

Procedural Redesign of VATS in Lung Cancer Improves Quality of Care and Reduces Cost

May 12th 2020

Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery.

Procedural Redesign of VATS in Lung Cancer Improves Quality of Care and Reduces Cost

May 12th 2020

Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery, without sacrificing quality of care.

Sawyers Explains Lessons Learned After Atezolizumab/Enzalutamide Falls Short in mCRPC

May 8th 2020

Charles L. Sawyers, MD, discusses the implications of the IMbassador250 trial, other notable presentations delivered at the meeting, and exciting research efforts being made in prostate cancer and beyond.

New MDS Subtype Recognized Based on Presence of Common Genetic Variant

May 8th 2020

The International Working Group for the Prognosis of MDS has identified a distinct subtype of myelodysplastic syndromes based on the presence of SF3B1, a nonheritable genetic mutation that causes the disease.

Onvansertib Regimen Shows Early Promise in KRAS-Mutant mCRC

May 7th 2020

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Addition of Novel Hormonal Agents to Standard Therapy Explored in Node-Positive Prostate Cancer

May 6th 2020

Investigators are examining if the addition of apalutamide, abiraterone acetate, and prednisone to standard hormone and radiation therapy will be more effective than standard treatment alone in node-positive prostate cancer.

Algazi Attests to Benefit of Continuous Dosing of BRAF/MEK Inhibitors in Melanoma

May 6th 2020

Alain Algazi, MD, discusses the SWOG S1320 trial further, the future of intermittent dosing in melanoma, and future clinical trials in the field.

NEXT PAGE
PREVIOUS PAGE